Epstein Secrets

From: Richard Kahn Sent: 12/15/2016 5:46:20 PM To: jeffrey E. [[email protected]] Subject: Fwd: US Healthcare Year Ahead...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW,

From: Richard Kahn Sent: 12/15/2016 5:46:20 PM To: jeffrey E. [jeev

n pockets) but pipelines/growth remains. Ying’s top picks are CELG & REGN; Tazeen’s top picks are ACAD & RARE. Spec Pharma (-) — headwinds remain w/ Sumant’s top pick AGN given lower risk to reimbursement pressures & an underappreciated pipeline. Leverage & CF remain the key focus for investors. Tools/A

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

e loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, I'd argue that

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connections"' From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

"Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

e loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, • argue that

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subj

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:43:38 +0000 agreed her frequent recommendati

e loss on 2 of its 5 Copaxone patents from yesterday's IPR decisions & MYL confirming that the third IPR decision is expected by 1-Sept, our analyst Sumant has notes out on TEVA, MYL & MNTA walking through his assumptions/thoughts. For TEVA, while today's ruling is somewhat of a setback, I'd argue that

From: Richard Kahn Sent: Thursday, December 15, 2016 5:46 PM To: Jeffrey E. Subject: Fwd: US Healthcare Year Ahead...Buy ACAD, AGN, ANTM, CELG, CVS, DI-IR, EW, EV

Healthcare =ear Ahead...Buy ACAD, AGN, ANTM, CELG, CVS, DHR, EW, EVHC, RARE, REGN, =BA Date: =/b>December 15, 2016 at 10:59:39 =M EST To: =/b>"Rich Kahn' Reply-To: =/b>"Ens, Amanda" The =S team is out with their 2017 Year Ahead this morning (link) running through =LL sub-sectors with each analysts t

) but pipelines/growth remains. Ying's top =icks are CELG =amp; REGN;=Tazeen's top picks are ACAD =amp; RARE. Spec Pharma (-) — =eadwinds remain w/ Sumant's top =ick AGN =iven lower risk to reimbursement pressures & an underappreciated =ipeline. =/span>Leverage & CF remain the key focus for investors.